Tag: Sangamo Therapeutics

Sangamo Therapeutics is advancing decisively with its investigational gene therapy, ST-920, for Fabry disease. The company has submitted critical data ...

As Sangamo Therapeutics advances its gene therapy candidate for Fabry disease, investor focus is split between imminent regulatory milestones and ...

Investor attention is firmly fixed on Sangamo Therapeutics as the company approaches several pivotal near-term events. The dual catalysts of ...

Sangamo Therapeutics has announced a series of strategic moves, including detailed clinical trial data and the initiation of a regulatory ...

Market analysts are pointing to a potential inflection point for Sangamo Therapeutics, with consensus estimates suggesting the biotech firm could ...

After a prolonged period of significant share price declines, Sangamo Therapeutics is back in the spotlight following a critical regulatory ...

Sangamo Therapeutics finds itself navigating perilous financial waters, with its stock experiencing a dramatic 21% decline following disappointing quarterly results ...